Ceftazidime
Ceftazidime is a pharmaceutical drug with 21 clinical trials. Currently 1 active trials ongoing. Historical success rate of 76.9%.
Success Metrics
Based on 10 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
4
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
76.9%
10 of 13 finished
23.1%
3 ended early
1
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Early Optimization of Ceftazidime Regimen in Critical Care
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients
Clinical Trials (21)
Early Optimization of Ceftazidime Regimen in Critical Care
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients
Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
Antibiotic Therapy vs Laparscopic Appendectomy in Pediatric Chronic Appendicitis
Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately
Lung Concentrations of Ceftazidime in Patients With Ventilator-associated Pneumonia
Post ERCP Pancreatitis Prevention in Average Risk Patients
Population Pharmacokinetics of Anti-infectious Drugs in Children
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration
Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 21